What would prompt discontinuing treatment versus switching or sequencing treatment in patients treated with an anti-amyloid therapy for Alzheimer's?  

To be sure, there is virtually no evidence of outcomes on switching from one antibody to another. If treatment discontinuation occurred due to ARIA, I would strongly discourage rechallenge with another agent. There is no rationale for discontinuing lecanemab or donanemab for lack of efficacy on clin...

There are guidelines to stop the medication due to ARIA. In my practice, we only discontinued treatment once, and it was due to the personal choice of the patient and family. I do not see a reason to switch from one medication to the other based on the data we currently have.

I would discontinue therapy if: If patients wish to discontinue. Development of side effects including ARIA. New medical problems warranting treatments that are contraindicated with concurrent anti-amyloid treatment. I do not offer sequencing therapy with the alternative agent if initial the...